GlassScriptPhysician profile
Mary A Weaver
NPI 1265795595
$12,195.35
in general payments reported to CMS, 2019-2025
46 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $1,117 · 2021: $2,837 · 2022: $1,784 · 2023: $1,804 · 2024: $1,703 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,305.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,600.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,301.33 | 2021 | |
| Lilly USA, LLC | $1,169.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,045.95 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $923.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $900.53 | 2019-2025 | Jardiance |
| Pfizer INC. | $759.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $535.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $404.92 | 2019-2025 | Spravato |
| Amgen INC. | $396.77 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $367.78 | 2019-2024 | Belsomra, Steglatro, Gardasil |
| Amarin Pharma, INC. | $323.25 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $224.05 | 2022 | |
| Allergan, INC. | $220.55 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.95 | 2019-2025 | Xifaxan, Trulance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.